A low-income nation’s bold approval of a twice-yearly HIV preventive injection sends a powerful message: the future of global health innovation may now flow through Africa, not around it.
By Collins Mtika
Malawi was not expected to move first, but it did. With a speed that jolted global health agencies, the country approved the twice-yearly HIV prevention shot lenacapavir in only 46 days, a regulatory sprint that positions this small nation as an unlikely pace-setter in the world’s fight against HIV.
Lilongwe’s Pharmacy and Medicines Regulatory Authority (PMRA), together with the National AIDS Commission (NAC), announced the registration of lenacapavir on December 4, 2025. At face value, it was a standard regulatory notice.
In reality, it marked one of the most decisive moments in global HIV prevention in years.
Gilead Sciences Ireland UC submitted its application on October 13, 2025. By November 28, PMRA had completed its scientific review, achieving in six weeks what often takes regulatory agencies in wealthier countries several months.
The accelerated approval was made possible by the Collaborative Registration Procedure (CRP) with the European Medicines Agency (EMA) and the World Health Organization (WHO).
This reliance-based model allowed Malawi to draw on the EMA’s scientific assessment rather than repeat it, a shift from duplication to intelligent regulatory networking.
“The expedited registration showcases PMRA’s unwavering commitment to fast-tracking access to high-quality, safe, and effective medicines,” said Mphatso Kawaye, PMRA Director General.
The achievement is particularly striking for a country where health budgets are chronically stretched and public systems frequently dismissed as slow or overwhelmed.
Malawi remains one of the global epicentres of HIV:
- Adult prevalence (15–49): ~8%
- Annual new infections: ~20,000
- Women and adolescent girls: nearly 60% of new infections
Despite decades of progress, the challenge of prevention persists, largely due to adherence difficulties with daily oral PrEP. In many rural districts, a young woman carrying PrEP pills risks stigma, misunderstanding, or accusations of being HIV-positive.
A twice-yearly injection bypasses these barriers.
“Its twice-yearly administration significantly reduces dosing burden and minimises the frequency of healthcare facility visits,” Dr Beatrice Matanje, CEO of the National AIDS Commission, said.
Malawi currently offers daily PrEP countrywide and is piloting bimonthly Cabotegravir (CAB-LA) in four districts. But lenacapavir, requiring just two visits a year, changes the calculus.
It can be easily integrated into routine health appointments, including family planning visits, antenatal care, or general outpatient services.
For many, HIV prevention becomes “invisible,” reducing stigma and improving uptake.
The regulatory win clears one hurdle but exposes another: cost. Lenacapavir’s price in high-income countries reaches tens of thousands of dollars per patient annually, far beyond what any low-income country can absorb. Malawi’s GDP per capita is roughly $600.
The government’s mention of a “phased approach” signals ongoing negotiations with:
- Gilead Sciences (for tiered pricing or licensing)
- The Medicines Patent Pool (for future generics)
- Major funders, including the Global Fund and PEPFAR
This dynamic echoes the early 2000s, when lifesaving HIV treatment was priced out of reach across the Global South. Yet today, African health ministries and civil society are far more assertive, and donors face increased scrutiny.
Malawi’s rapid action now forces a difficult question: will global funders match the country’s urgency with equally swift financing?
Malawi’s regulatory speed may inspire a wave of approvals across the Southern African Development Community (SADC), especially in Zambia, Zimbabwe, and Mozambique, countries with similar epidemiological profiles and mobile populations.
More broadly, Malawi’s adoption of the CRP signals a new regulatory era:
- African agencies can achieve speed without compromising safety.
- Reliance approaches cut costs and duplication.
- Regional cooperation can accelerate access to essential medicines.
As climate change drives new and more frequent health emergencies, cholera surges, malaria shifts, and emerging viral infections, such regulatory agility may prove indispensable.
Regulatory approval is only the first step. Implementation presents its own set of challenges:
- Ensuring cold-chain storage for biologics
- Training nurses and frontline health workers
- Managing stock levels and supply chains
- Addressing community fears and misinformation
- Securing sustainable financing for long-term rollout
If these challenges are not addressed early, the promise of lenacapavir could be compromised before the first injection is widely delivered.
As 2026 approaches, public health experts will closely monitor Malawi’s rollout.
If the country can successfully deploy a twice-yearly, vaccine-like HIV preventive treatment at scale, it could transform HIV prevention across Africa and possibly end the epidemic’s grip on entire regions.
Malawi has demonstrated that the barriers to ending HIV are no longer based in science. The science is ready. The obstacles now are political, logistical, and financial.
And Malawi, in just 46 days, has cleared two of them.
The world must ensure the third does not become the one that stops a breakthrough approved with such unprecedented speed.
